Collinson, F, Brown, S, Buckley, H orcid.org/0000-0002-9829-5817 et al. (11 more authors) (2018) PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. Annals of Oncology (Part of special issue:Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany), 29 (8). viii331-viii331. ISSN 0923-7534
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2018 The Authors. Published by Elsevier Ltd. All rights reserved. This article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed. |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM) > Clinical & Population Science Dept (Leeds) The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds) |
Funding Information: | Funder Grant number Bristol Myers Squibb PRISM |
Depositing User: | Symplectic Publications |
Date Deposited: | 16 Mar 2020 10:05 |
Last Modified: | 16 Mar 2020 10:05 |
Status: | Published |
Publisher: | Elsevier |
Identification Number: | 10.1093/annonc/mdy283.140 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:158436 |
Download
Filename: PRISM_abstract_AnnalsOncology_2018_931TiP.pdf
Licence: CC-BY-NC-ND 4.0